OncoMed Pharmaceuticals Inc (OMED.O) Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company’s anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-! based therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
News about OMED
Price of Silver Drops, Here's Where It's Headed Next
Peter KrauthThe price of silver today is down 0.34% in morning trading, as the Federal Reserve's next meeting approaches. However, silver prices could be gearing up for a new rally. The grey metal has been consolidating sideways since early ...Read More>>>
A Perfect Track Record for Quick Double-Digit Gains
Today, I'll share a trade that has a perfect track record in recent years... More important, it just signaled again. If you follow this signal, you should be able to pocket double-digit gains in six months on a "bor...Read More>>>
Oil Is Breaking Out -- Profit With These 3 MLPs
Last year, I wrote a somewhat bearish article on the long-term price of oil. While I am sticking to my guns long-term, a recent research piece published by Confluence Investment Management's Bill O'Grady (one of the best energy analysts) sets a near-...Read More>>>
Life after 50: freedom, simplicity, new horizons
This article is reprinted by permission from NextAvenue.org. It is excerpted and adapted from “How Do I Get There From Here? Planning for Retirement When the Old Rules No Longer Apply” by George H. Schofield, Ph.D. It’s an uninformed and inac...Read More>>>
When are we going to see a truly great video game movie?
Warner Bros. and Metro-Goldwyn-Mayer tried to pull off one of the riskiest feats in Hollywood this weekend: a successful video game movie adaptation. "Tomb Raider" took in about $23.5 million at the domestic box office in its opening weekend, accord...Read More>>>